お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
907678

大腸がん:世界市場の見通し(2017年~2026年)

Colorectal Cancer - Global Market Outlook (2017-2026)

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 137 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.68円
大腸がん:世界市場の見通し(2017年~2026年)
出版日: 2019年08月19日
発行: Stratistics Market Research Consulting
ページ情報: 英文 137 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の大腸がん市場は、2017年に92億2,000万米ドルとなりました。同市場は、2017年から2026年の間に3.9%のCAGRで成長する見通しで、2026年には130億1,000万米ドルに達すると予測されています。新薬および改善された治療薬の導入、高価なブランド治療薬の普及、政府や民間組織によるいくつかのイニシアチブは、市場の成長を後押しする要因の一部です。

当レポートは世界の大腸がん市場について調査しており、市場機会、成長および阻害要因、新興市場や脅威、療法および薬剤・検査及び診断・手順・製品・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

  • イントロダクション
  • 成長要因
  • 阻害要因
  • 市場機会
  • 脅威
  • 製品分析
  • 用途分析
  • 新興市場
  • 将来の市場シナリオ

第4章 ポーターのファイブフォース分析

  • サプライヤーの交渉力
  • バイヤーの交渉力
  • 代用品の脅威
  • 新規参入の脅威
  • 業界内の競争

第5章 世界市場:療法及び薬剤別

  • イントロダクション
  • 化学療法
  • 免疫療法
  • 放射線療法
  • 外科手術
  • その他の治療

第6章 世界市場:検査および診断別

  • イントロダクション
  • 免疫化学
  • 肉眼検査
  • 顕微鏡検査
  • ステージング
  • 簇出

第7章 世界市場:手順別

  • イントロダクション
  • 生検
  • 人工肛門
  • MRI
  • マンモグラフィ
  • S状結腸鏡検査

第8章 世界市場:製品別

  • イントロダクション
  • フローサイトメトリー
  • in situ ハイブリダイゼーション
  • マイクロアレイ
  • 次世代シーケンシング
  • 標的療法

第9章 世界市場:用途別

  • イントロダクション
  • 病院および診療所
  • その他

第10章 世界市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他
  • 中東・アフリカ地域
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他

第11章 主な開発

  • 契約、協業、提携、および合弁事業
  • 買収および合併
  • 新製品の発売
  • 拡張
  • その他の主要戦略

第12章 企業プロファイル

  • Abbott Laboratories
  • Amgen Inc.
  • Clinical Genomics
  • EDP Biotech
  • Epigenomics AG
  • Hoffmann-La Roche AG
  • Novigenix SA
  • Quest Diagnostics
  • Sanofi SA
  • Siemens Healthineers
  • VolitionRX
図表

List of Tables

  • 1 Global Colorectal Cancer Market Outlook, By Region (2016-2026) ($MN)
  • 2 Global Colorectal Cancer Market Outlook, By Therapies & Drugs (2016-2026) ($MN)
  • 3 Global Colorectal Cancer Market Outlook, By Chemo Therapy (2016-2026) ($MN)
  • 4 Global Colorectal Cancer Market Outlook, By Alkylating Agent - Oxaliplatin (Eloxatin) (2016-2026) ($MN)
  • 5 Global Colorectal Cancer Market Outlook, By Antimetabolites (2016-2026) ($MN)
  • 6 Global Colorectal Cancer Market Outlook, By Immuno Therapy (2016-2026) ($MN)
  • 7 Global Colorectal Cancer Market Outlook, By Biologic Response Modifiers (2016-2026) ($MN)
  • 8 Global Colorectal Cancer Market Outlook, By Colony-Stimulating Factors (2016-2026) ($MN)
  • 9 Global Colorectal Cancer Market Outlook, By Monoclonal Antibodies (2016-2026) ($MN)
  • 10 Global Colorectal Cancer Market Outlook, By Tumor Vaccines (2016-2026) ($MN)
  • 11 Global Colorectal Cancer Market Outlook, By Radiation Therapy (2016-2026) ($MN)
  • 12 Global Colorectal Cancer Market Outlook, By Surgery (2016-2026) ($MN)
  • 13 Global Colorectal Cancer Market Outlook, By Others Therapies & Drugs (2016-2026) ($MN)
  • 14 Global Colorectal Cancer Market Outlook, By Testing & Diagnosis (2016-2026) ($MN)
  • 15 Global Colorectal Cancer Market Outlook, By Immunochemistry (2016-2026) ($MN)
  • 16 Global Colorectal Cancer Market Outlook, By Macroscopy (2016-2026) ($MN)
  • 17 Global Colorectal Cancer Market Outlook, By Microscopy (2016-2026) ($MN)
  • 18 Global Colorectal Cancer Market Outlook, By Staging (2016-2026) ($MN)
  • 19 Global Colorectal Cancer Market Outlook, By Tumor Budding (2016-2026) ($MN)
  • 20 Global Colorectal Cancer Market Outlook, By Procedure (2016-2026) ($MN)
  • 21 Global Colorectal Cancer Market Outlook, By Biopsy (2016-2026) ($MN)
  • 22 Global Colorectal Cancer Market Outlook, By Colostomy (2016-2026) ($MN)
  • 23 Global Colorectal Cancer Market Outlook, By Magnetic Resonance Imaging (MRI) (2016-2026) ($MN)
  • 24 Global Colorectal Cancer Market Outlook, By Mammography (2016-2026) ($MN)
  • 25 Global Colorectal Cancer Market Outlook, By Sigmoidoscopy (2016-2026) ($MN)
  • 26 Global Colorectal Cancer Market Outlook, By Product (2016-2026) ($MN)
  • 27 Global Colorectal Cancer Market Outlook, By Flow Cytometry (2016-2026) ($MN)
  • 28 Global Colorectal Cancer Market Outlook, By In Situ Hybridization (2016-2026) ($MN)
  • 29 Global Colorectal Cancer Market Outlook, By Microarrays (2016-2026) ($MN)
  • 30 Global Colorectal Cancer Market Outlook, By Next-Generation Sequencing (2016-2026) ($MN)
  • 31 Global Colorectal Cancer Market Outlook, By Targeted Therapy (2016-2026) ($MN)
  • 32 Global Colorectal Cancer Market Outlook, By Application (2016-2026) ($MN)
  • 33 Global Colorectal Cancer Market Outlook, By Hospitals and Clinics (2016-2026) ($MN)
  • 34 Global Colorectal Cancer Market Outlook, By Other Applications (2016-2026) ($MN)

NOTE: The tables for North America, Europe, APAC, Middle East, Latin America, and Rest of the World Regions are also represented in the same manner as above.

目次

According to Stratistics MRC, the Global Colorectal Cancer Market is accounted for $9.22 billion in 2017 and is expected to reach $13.01 billion by 2026 growing at a CAGR of 3.9% during the forecast period. Introduction of new and improved therapies and drugs, the rising uptake of higher-priced branded therapies, and several initiatives by governments and private organizations are some of the factors fuelling the market growth. However, factors such as the reluctance toward colorectal cancer medications on the part of patients and a lack of awareness in many parts of the world will pose a threat to the growth of the overall market.

Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar risk factors and symptoms mean that they are often grouped together. CRC is believed to arise as a result of interactions between inherited and environmental factors. Despite improved prognosis of CRC patients in the last decade following advances in treatment options, survival rates still lag behind those of breast and prostate cancer patients.

Based on therapies & drugs, the increasing awareness for treating colorectal cancer by chemotherapy and immunotherapy propels the industry growth during the forecast period. By Geography, North America is a key region in the market and estimated to have a lucrative growth in terms of demand and revenue. This market is fueled by a number of factors, the primary one being greater prevalence of colorectal cancer.

Some of the key players profiled in the Colorectal Cancer market include Abbott Laboratories, Amgen Inc., Clinical Genomics, EDP Biotech, Epigenomics AG, Hoffmann-La Roche AG, Novigenix SA, Quest Diagnostics, Sanofi SA, Siemens Healthineers and VolitionRX.

Therapies & Drugs Covered:

  • Chemo Therapy
  • Immuno Therapy
  • Radiation Therapy
  • Surgery
  • Others Therapies & Drugs

Testing & Diagnosis Covered:

  • Immunochemistry
  • Macroscopy
  • Microscopy
  • Staging
  • Tumor Budding

Procedures Covered:

  • Biopsy
  • Colostomy
  • Magnetic Resonance Imaging (MRI)
  • Mammography
  • Sigmoidoscopy

Products Covered:

  • Flow Cytometry
  • In Situ Hybridization
  • Microarrays
  • Next-Generation Sequencing
  • Targeted Therapy

Applications Covered:

  • Hospitals and Clinics
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Colorectal Cancer Market, By Therapies & Drugs

  • 5.1 Introduction
  • 5.2 Chemo Therapy
    • 5.2.1 Alkylating Agent - Oxaliplatin (Eloxatin)
    • 5.2.2 Antimetabolites
      • 5.2.2.1 Capecitabine (Xeloda)
      • 5.2.2.2 Fluorouracil (Adrucil)
  • 5.3 Immuno Therapy
    • 5.3.1 Biologic Response Modifiers
    • 5.3.2 Colony-Stimulating Factors
    • 5.3.3 Monoclonal Antibodies
      • 5.3.3.1 Bevacizumab (Avastin)
      • 5.3.3.2 Cetuximab (Erbitux)
      • 5.3.3.3 Panitumumab (Vectibix)
    • 5.3.4 Tumor Vaccines
  • 5.4 Radiation Therapy
  • 5.5 Surgery
  • 5.6 Others Therapies & Drugs

6 Global Colorectal Cancer Market, By Testing & Diagnosis

  • 6.1 Introduction
  • 6.2 Immunochemistry
  • 6.3 Macroscopy
  • 6.4 Microscopy
  • 6.5 Staging
  • 6.6 Tumor Budding

7 Global Colorectal Cancer Market, By Procedure

  • 7.1 Introduction
  • 7.2 Biopsy
  • 7.3 Colostomy
  • 7.4 Magnetic Resonance Imaging (MRI)
  • 7.5 Mammography
  • 7.6 Sigmoidoscopy

8 Global Colorectal Cancer Market, By Product

  • 8.1 Introduction
  • 8.2 Flow Cytometry
  • 8.3 In Situ Hybridization
  • 8.4 Microarrays
  • 8.5 Next-Generation Sequencing
  • 8.6 Targeted Therapy

9 Global Colorectal Cancer Market, By Application

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Other Applications

10 Global Colorectal Cancer Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Amgen Inc.
  • 12.3 Clinical Genomics
  • 12.4 EDP Biotech
  • 12.5 Epigenomics AG
  • 12.6 Hoffmann-La Roche AG
  • 12.7 Novigenix SA
  • 12.8 Quest Diagnostics
  • 12.9 Sanofi SA
  • 12.10 Siemens Healthineers
  • 12.11 VolitionRX
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.